At a glance
- Originator Novartis
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Iron overload
Most Recent Events
- 18 Jun 1999 New profile
- 18 Jun 1999 Preclinical development for Iron overload in England (Unknown route)